Cannabis and depression
Browse the latest research linking medical marijuana / medicinal cannabis and depression.
Click on a study title below to open a new tab with full article, or click on a compound to see it's full list of research.
Compounds Topics Title Date
cannabis anxiety,pain,depression in humans via survey (n=3341) The Association between Cannabis Product Characteristics and Symptom Relief Feb 2019
Patients showed an average symptom improvement of 3.5 (SD = 2.6) on an 11-point scale across the 27 measured symptom categories. Dried flower was the most commonly used product and generally associated with greater symptom relief than other types of products.
Linalool,Pinene depression in mice via experiment antidepressant activity of Litsea glaucescens essential oil: Identification of Beta-pinene and linalool as active principles Sept 2012
Ingestion Method: 100 and 300 mg/Kg.
L. glaucescens essential oil showed antidepressant activity, beta--pinene and linalool were identified as its active principles. These results support the use of L. glaucescens in Mexican Traditional Medicine for the treatment of sadness.
Limonene,Phellandrene pain,depression in rats via experiment Antihyperalgesic and antidepressive actions of (R)-(+)-limonene, Alpha-phellandrene, and essential oil from Schinus terebinthifolius fruits in a neuropathic pain model. July 2015
Together, the results of the present work show that essential oil of S. terebinthifolius and compounds present in this oil, including (R)-(+)-limonene and alpha--phellandrene, exhibit antihyperalgesic effects against mechanical hyperalgesia, and are antidepressive,
Caryophyllene depression,anxiety in mice Beta-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice Aug 2014
Ingestion Method: 50mg/kg
Taken together, these preclinical results suggest that CB2 receptors may provide alternative therapeutic targets for the treatment of anxiety and depression. The possibility that BCP may ameliorate the symptoms of these mood disorders offers exciting prospects for future studies.
Linalool,Pinene depression in mice Linalool and Beta-pinene exert their antidepressant-like activity through the monoaminergic pathway. May 2015
Our results indicate that linalool and beta--pinene produce an antidepressant-like effect through interaction with the monoaminergic system.
CBD depression in rats via experiment Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors. Apr 2016
Ingestion Method: 10-60 nmol injection
Action Pathway: 5HT1A,CB1
CBD (PL: 10-60 nmol; IL:45-60 nmol) and 8-OH-DPAT (10 nmol) administration significantly reduced the immobility time in the FST, without changing locomotor activity in the OFT
CBD depression in mice Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex. Jun 2018
Ingestion Method: 7-30 mg/kg
Action Pathway: BDNF
These results indicate that CBD induces fast and sustained antidepressant-like effect in distinct animal models relevant for depression. These effects may be related to rapid changes in synaptic plasticity in the mPFC through activation of the BDNF-TrkB signaling pathway. The data support a promising therapeutic profile for CBD as a new fast-acting antidepressant drug.
Caryophyllene diabetes,pain,depression in mice via experiment Beta-Caryophyllene, a Natural Sesquiterpene, Attenuates Neuropathic Pain and Depressive-Like Behavior in Experimental Diabetic Mice Mar 2019
Ingestion Method: oral 10 mg/kg/60 ?L
Our data using an orally chronic BCP administration in the STZ challenged mice to suggest that glycemia, diabetes-related NP, and depressive-like behavior could be prevented/reduced by dietary BCP.
cannabis pain,anxiety,depression in humans via review Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis Jun 2019
Positive  Meta-analytic results indicated that pain (64%), anxiety (50%), and depression/mood (34%) were common reasons for medical cannabis use. No evidence for publication bias was detected, despite heterogeneity in prevalence rates.